Gonadorelin (GnRH) Research Overview

What Is Gonadorelin?

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), the endogenous hypothalamic decapeptide that governs the reproductive axis in all mammals. Its chemical structure is a 10-amino acid sequence: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, with a molecular weight of 1182.33 Da. It is also designated as luteinizing hormone-releasing hormone (LHRH), reflecting its primary action of stimulating pituitary LH release.

Gonadorelin is distinct from synthetic GnRH agonist analogues such as leuprolide (Lupron), buserelin, and nafarelin, which are structural modifications designed to resist enzymatic degradation and produce prolonged, paradoxically suppressive receptor stimulation. Gonadorelin itself has a very short half-life and, when administered in pulses, stimulates rather than suppresses gonadotropin release.

Discovery and Nobel Prize Background

The isolation and characterization of GnRH represents one of the landmark achievements in endocrinology. Andrew V. Schally and Roger C.L. Guillemin independently and simultaneously determined the structure of GnRH in 1971 after years of competing research: Schally's group processed approximately 2.5 million pig hypothalami and Guillemin's group approximately 5 million sheep hypothalami to obtain sufficient quantities for structural analysis.

Both announced the GnRH structure in 1971. This work, along with Rosalyn Yalow's development of radioimmunoassay, was recognized by the 1977 Nobel Prize in Physiology or Medicine, shared by Schally, Guillemin, and Yalow. The identification of GnRH as the master regulator of the reproductive axis opened the door for the development of GnRH agonists and antagonists that have transformed the treatment of prostate cancer, endometriosis, precocious puberty, and infertility.

Mechanism of Action

Gonadorelin binds to GnRH receptors (GnRHR) on anterior pituitary gonadotroph cells. GnRHR is a Gq/11-coupled seven-transmembrane receptor. Ligand binding activates phospholipase C, generating IP3 and DAG, which triggers intracellular calcium release and protein kinase C activation. This cascade stimulates synthesis and secretion of both LH and FSH.

Endogenous GnRH is secreted in pulses by the hypothalamus approximately every 60–120 minutes. The pulsatile pattern is essential: intermittent stimulation sustains GnRHR expression and gonadotropin secretion, while continuous stimulation triggers receptor downregulation and gonadotropin suppression (the principle exploited by GnRH agonist drugs used in prostate cancer and endometriosis).

LH acts on Leydig cells in the testes to stimulate testosterone synthesis; in women, LH drives ovulation and progesterone production from the corpus luteum. FSH acts on Sertoli cells in men to support spermatogenesis and on granulosa cells in women to drive follicular development.

Research and Approved Uses

Gonadorelin (as Factrel, Wyeth/Pfizer) was FDA-approved for two indications: (1) evaluating the functional capacity and response of the gonadotrophs in patients with suspected gonadotropin deficiency (a diagnostic test), and (2) evaluating residual gonadotropic function in pituitary surgery or radiation patients.

A related product, gonadorelin acetate delivered by pulsatile pump (Lutrepulse, formerly Cystorelin), was approved for ovulation induction in women with primary hypothalamic amenorrhea. Pulsatile pump delivery mimics physiological GnRH secretion, making it effective for restoring gonadotropin pulsatility in women with hypothalamic dysfunction.

The seminal characterization of GnRH structure and function has generated decades of research into its downstream applications. A 2023 PMC review marking the 50-year anniversary of GnRH's discovery (PMC10201296) summarized the compound's continuing relevance in reproductive endocrinology and oncology.

Current US Availability: Factrel Discontinuation and Compounded Gonadorelin

FDA-approved branded gonadorelin (Factrel) was discontinued by Pfizer. The product has not been commercially available in the United States from the original manufacturer. As of 2024, the DailyMed listing for Factrel (NLM set ID: 1451663c) shows the product is no longer actively marketed. This is a voluntary manufacturer discontinuation, not an FDA safety-based withdrawal.

The practical gap left by Factrel's discontinuation has been filled, in part, by compounding pharmacies. 503A state-licensed compounding pharmacies in the US now prepare injectable gonadorelin solutions, predominantly for use in men's health and testosterone replacement therapy (TRT) protocols. The compounded product is prescribed off-label to mitigate testicular atrophy and preserve intratesticular testosterone production and spermatogenesis in men receiving exogenous testosterone, in whom the HPG axis is suppressed.

It is important to note that the off-label TRT-adjunct use of compounded gonadorelin differs substantially from the original FDA-approved diagnostic indication. The evidence base for gonadorelin as a TRT adjunct is currently limited to small observational series and clinical reasoning extrapolated from the GnRH physiology literature. Compounded gonadorelin is not the same product as FDA-approved Factrel, and compounding quality and sterility standards vary by pharmacy.

Pharmacokinetics

Gonadorelin is rapidly cleared from plasma following intravenous or subcutaneous administration. The plasma half-life is approximately 2–4 minutes after IV administration, and somewhat longer (10–40 minutes) after subcutaneous injection, owing to slower absorption from subcutaneous tissue. The peptide is degraded by plasma proteases and endopeptidases, primarily at the Tyr5-Gly6 and Gly6-Leu7 bonds.

LH and FSH responses following an IV bolus of gonadorelin peak within 20–60 minutes and return toward baseline within 2–3 hours. The diagnostic test (Factrel stimulation test) exploited this kinetic profile: a blood sample drawn 30 minutes post-injection captures the LH peak, providing an index of pituitary gonadotroph reserve.

FDA-Approved Indications and Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Based on the Factrel FDA label (now discontinued from commercial supply): The FDA label specifies 100 mcg as a single intravenous or subcutaneous bolus dose for the diagnostic stimulation test. Blood samples for LH and FSH are drawn at baseline and at 15 and 30 minutes post-injection. While the branded product is no longer commercially available, the label parameters inform clinical practice and compounding specifications.

Storage and Stability

As a lyophilized powder (the Factrel formulation), gonadorelin should be stored at room temperature (approximately 15–25 °C), protected from light, and reconstituted with the accompanying diluent immediately before use. Reconstituted solutions should be used promptly and not stored. Compounded injectable gonadorelin preparations typically specify refrigerated storage at 2–8 °C; the specific stability data will vary by compounding pharmacy and formulation.

What Gonadorelin Is Not

Gonadorelin is not the same compound as leuprolide (Lupron, Eligard), buserelin, nafarelin, triptorelin, or histrelin. These are synthetic GnRH agonist analogues with structural modifications that confer high GnRH receptor affinity and resistance to enzymatic degradation, producing prolonged receptor occupancy and downstream gonadotropin suppression — the opposite of gonadorelin's pulsatile stimulatory effect.

Gonadorelin is also not a GnRH antagonist (such as degarelix or relugolix), which block the receptor directly without initial stimulation. Kisspeptin, a separate upstream regulator of GnRH neurons, is a distinct peptide that modulates gonadorelin's endogenous release but is not interchangeable with gonadorelin itself.

References

See citations below.